• Product NameENMD-2076
• Brief DescriptionInhibitors
• Purification98.00%
• Biological ActivityENMD-2076 has selective activity against Aurora A and Flt3 with IC50 of 14 nM and 1.86 nM, 25-fold selective for Aurora A than over Aurora B and less potent to VEGFR2/KDR and VEGFR3, FGFR1 and FGFR2 and PDGFRα. Phase 2.
• Target NameAurora Kinase inhibitor; c-RET inhibitor; FLT inhibitor; Src inhibitor; VEGFR inhibitor
• CAS No. 934353-76-1
• Calculated MW 375.47
• Formulation C21H25N7
• Storage 3 years -20˚C powder;2 years -80˚C in solvent;

• Research Area:Cancer
  SMILES:CC1=CC(=NN1)NC2=NC(=NC(=C2)N3CCN(CC3)C)/C=C/C4=CC=CC=C4
  Pathways:Cell Cycle/Checkpoint; Angiogenesis; Apoptosis; Chromatin/Epigenetic; Tyrosine Kinase/Adaptors
  Receptor:Aurora A; RET; FLT3; Src; VEGFR3/FLT4
  Boling pt:
  Melting pt:
  Solubility:Water: 1 mg/mL (2.66 mM); DMSO: 105 mg/mL (279.64 mM)
  Appearance:Yellow Powder
  Remark:For obtaining a higher solubility , please warm the tube at 37 ˚C and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20 ˚C for several month.

1. Fletcher GC, et al, Mol Y Ther, 2011, 10(1), 126-137.

• Flow Cytometry (FCM) General Protocol
• Immunofluorescence(IC)
• Immunohistochemistry(Polymer)
• Western Blotting